J. Becker

发表

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.

M. Dougados, J. Kremer, M. Genovese, 2005, The New England journal of medicine.

Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial

J. Kremer, M. Weinblatt, Tracy T Li, 2006, Annals of the rheumatic diseases.

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

M. Dougados, M. Schiff, M. Schiff, 2007, Annals of the rheumatic diseases.

Rheumatoid arthritis - treatment 180. Utility of Body Weight Classified Low-Dose Leflunomide in Japanese Rheumatoid Arthritis

Stanley B. Cohen, D. Symmons, M. Dougados, 2011 .

The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial.

S. Bae, D. D'cruz, D. Wallace, 2010, Arthritis and rheumatism.

Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis.

M. Weisman, L. Moreland, P. Durez, 2006, The Journal of rheumatology.

Longterm Safety, Efficacy, and Inhibition of Structural Damage Progression Over 5 Years of Treatment with Abatacept in Patients with Rheumatoid Arthritis in the Abatacept in Inadequate Responders to Methotrexate Trial

H. Genant, J. Kremer, C. Peterfy, 2014, The Journal of Rheumatology.

Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion.

Stanley B. Cohen, P. Emery, L. Moreland, 2002, Arthritis and rheumatism.

State-of-the-Art Review: The Preclinical and Clinical Pharmacology of Novastan (Argatroban): A Small-Molecule, Direct Thrombin Inhibitor

J. Becker, T. Kogan, R. Schwarz, 1997 .

Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial

H. Genant, J. Kremer, C. Peterfy, 2007, Annals of the rheumatic diseases.

A phase I pharmacokinetics trial comparing PF‐05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis

Stanley B. Cohen, Dolca Thomas, P. Emery, 2016, British journal of clinical pharmacology.

Novastan® (Brand of Argatroban): A Small-Molecule, Direct Thrombin Inhibitor

Kenneth J. Alford, J. Becker, T. Kogan, 1997, Seminars in thrombosis and hemostasis.

Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis

H. Genant, W. Grassi, C. Peterfy, 2014, Annals of the rheumatic diseases.

Abatacept Plus Methotrexate Provides Incremental Clinical Benefits Versus Methotrexate Alone in Methotrexate-naive Patients with Early Rheumatoid Arthritis Who Achieve Radiographic Nonprogression

E. Keystone, R. Westhovens, A. Wells, 2011, The Journal of Rheumatology.

The Efficacy and Safety of Abatacept in SLE: Results of a 12-month Exploratory Study

S. Bae, D. D'cruz, D. Wallace, 2008 .

Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial

H. Genant, J. Kremer, C. Peterfy, 2011, Annals of the Rheumatic Diseases.

P31 Abatacept increases the proportion of patients who remain free from structural damage progression through 5 years in methotrexate inadequate responders with RA

J. Kremer, C. Peterfy, R. Westhovens, 2009 .

Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial.

D. Gladman, P. Tak, M. Genovese, 2011, Arthritis and rheumatism.

Safety and Efficacy of the Selective Costimulation Modulator Abatacept in Patients with Rheumatoid Arthritis Receiving Background Methotrexate: A 5-year Extended Phase IIB Study

M. Dougados, J. Kremer, P. Emery, 2009, The Journal of Rheumatology.

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial.

M. Dougados, J. Kremer, P. Emery, 2005, Arthritis and rheumatism.

Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes

H. Genant, W. Grassi, C. Peterfy, 2011, Annals of the rheumatic diseases.

Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate.

H. Genant, J. Kremer, P. Emery, 2008, Arthritis and rheumatism.

Multi-organ failure in a previously healthy 10-year-old boy: streptococcal toxic shock syndrome (STSS) - a rare differential diagnosis.

J. Becker, M. Imöhl, B. Gharavi, 2010, Klinische Padiatrie.

Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate

M. Dougados, P. V. van Riel, J. Smolen, 2008, Annals of the rheumatic diseases.

Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig.

M. Dougados, J. Kremer, P. Emery, 2003, The New England journal of medicine.

Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis

H. Genant, J. Kremer, P. Emery, 2006, Annals of Internal Medicine.

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors

H. Genant, W. Grassi, C. Peterfy, 2009, Annals of the rheumatic diseases.

Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)

M. Dougados, H. Genant, I. Logeart, 2009, Annals of the rheumatic diseases.

A single-arm, open-label study to assess the immunogenicity, safety, and efficacy of etanercept manufactured using the serum-free, high-capacity manufacturing process administered to patients with rheumatoid arthritis

P. Perić, J. Korth-Bradley, R. Pedersen, 2018, European journal of rheumatology.

Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study.

M. Weinblatt, E. Keystone, B. Combe, 2006, Arthritis and rheumatism.

The International Normalized Ratio during concurrent warfarin and argatroban anticoagulation: differential contributions of each agent and effects of the choice of thromboplastin used.

J. Zehnder, J. Becker, R. Schwarz, 1999, Clinical chemistry.

Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life.

J. Ware, M. Kosinski, P. Emery, 2006, The Journal of rheumatology.

Concise Report

M. Dougados, C. Poncet, M. Schiff, 2022 .

Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy

M. Dougados, M. Genovese, M. Schiff, 2007, Annals of the rheumatic diseases.

Improvements in participation in usual daily activities in patients with rheumatoid arthritis treated with abatacept.

P. Tugwell, P. Emery, G. Wells, 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

The Journal of Rheumatology Volume 36 , no . 4 5-year Extended Phase IIB Study Patients with Rheumatoid Arthritis Receiving Background Methotrexate : A Safety and Efficacy of the Selective Costimulation Modulator Abatacept in

M. Dougados, J. Kremer, P. Emery, 2009 .

Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment

P. Emery, J. Cole, A. Russell, 2006, Annals of the rheumatic diseases.

AN INTEGRATED SAFETY ANALYSIS OF ABATACEPT IN THE TREATMENT OF RHEUMATOID ARTHRITIS (RA) ACROSS PATIENT TYPES AND BACKGROUND THERAPIES: 145

M. Weinblatt, L. Moreland, J. Becker, 2006 .

Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation with Fusion Protein CTLA 4 Ig

M. Dougados, J. Kremer, P. Emery, 2003 .

Morbid anatomy of ‘erosive osteoarthritis’ of the interphalangeal finger joints: an optimised scoring system to monitor disease progression in affected joints

M. Dougados, P. Emery, G. Verbruggen, 2009, Annals of the rheumatic diseases.

The efficacy and safety of abatacept in methotrexate-naive patients with early erosive rheumatoid arthritis and poor prognostic factors

H. Genant, W. Grassi, C. Peterfy, 2008 .

Abatacept Plus Methotrexate Provides Incremental Clinical Benefits Versus Methotrexate Alone in Methotrexate-naive Patients with Early Rheumatoid Arthritis Who Achieve Radiographic Nonprogression

E. Keystone, R. Westhovens, A. Wells, 2011, The Journal of Rheumatology.

H. Genant, J. Kremer, C. Peterfy, 2014, The Journal of Rheumatology.

Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study

M. Dougados, C. Poncet, M. Schiff, 2011, Annals of the Rheumatic Diseases.

Interest of modelling in rheumatoid arthritis.

J. Becker, S. Merkesdal, A. Beresniak, 2012, Clinical and experimental rheumatology.

Comparative assessment of clinical response in patients with rheumatoid arthritis between PF‐05280586, a proposed rituximab biosimilar, and rituximab

M. Hutmacher, K. Liao, B. Gumbiner, 2016, British journal of clinical pharmacology.

The International Normalized Ratio during Concurrent Warfarin and Argatroban Anticoagulation: Differential Contributions of Each Agent and Effects of the Choice

J. Becker, R. Schwarz, M. Hursting, 1999 .